- Foremost aims to commercialize a technology that can convert dairy manufacturing co-products into environmentally friendly, value-added materials
- The partners aim to reduce the dairy industry’s carbon footprint while simultaneously lowering manufacturing costs and creating a significant new revenue stream for the hundreds of Midwest dairy farmer members comprising the Foremost Farms cooperative
- Foremost Farms will leverage Ginkgo’s bioproduction services and market-leading metabolic engineering and analytical capabilities to advance this novel technology
MIDDLETON, Wis. and BOSTON, Nov. 9, 2023 /PRNewswire/ — Foremost Farms USA, a world-class producer of cheese, butter, and dairy ingredients supplied to national and international markets, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to use advances in biotechnology to enable domestic, sustainable biomanufacturing of materials from dairy co-products to benefit the environment, family farms and the dairy industry as a whole.
Upcycling Dairy Co-products into Value-Added Materials
Through this partnership, Foremost Farms will leverage Ginkgo’s bioproduction services to develop and commercialize a new technology that could help upcycle billions of pounds of dairy co-products each year. Foremost Farms has selected Ginkgo as its partner of choice to develop a new upcycling technology because of Ginkgo’s leading metabolic engineering and analytical capabilities, which will allow strain optimization for challenging environmental conditions while avoiding common toxicity issues.
Reducing the Dairy Industry’s Carbon Footprint
Today, the dairy industry produces low-value co-products that contribute to their overall carbon footprint. Ginkgo aims to help Foremost build a technology to reduce this carbon footprint by upcycling these low-value co-products. This process could provide an environmentally friendly alternative to wasteful and carbon-intensive chemical production through domestic, sustainable biomanufacturing solutions.
“We’re excited to partner with Ginkgo Bioworks, which can uniquely help Foremost Farms realize its goals. Ginkgo’s platform gives us access to everything we need to move from concept to commercialization faster, providing a competitive advantage,” said Greg Schlafer, President and CEO, Foremost Farms. “We are innovating to continue our trajectory as environmental stewards that take care of our world and create value for dairy farm families by potentially lowering manufacturing costs and creating a significant new revenue stream for those farmers.”
“Ginkgo is always on the lookout for opportunities to use biology to create more sustainable products, and we are especially interested in helping customers in legacy industries develop improved production processes and a more circular economy,” said Jennifer Wipf, Ginkgo’s Head of Commercial, Cell Engineering. “We’re eager to put our advanced metabolic engineering capabilities to work for Foremost Farms and are proud to help accelerate efforts focused on sustainable biomanufacturing.”
“We’re in a unique position to leverage Ginkgo’s expertise because their flexible R&D service offerings allow us to creatively approach this significant opportunity in our value chain,” said Declan Roche, Chief Commercial Officer at Foremost Farms. “With Ginkgo, we’re able to pursue this exciting opportunity while minimizing our internal R&D fixed costs and allowing our team to remain focused on our core business.”
About Foremost Farms USA
Foremost Farms USA® is a dairy cooperative with hundreds of Midwest dairy farmer members located across seven Midwest states, including Illinois, Indiana, Iowa, Michigan, Minnesota, Ohio and Wisconsin – America’s Dairyland. It is one of the largest, leading dairy cooperatives in the United States and a major food manufacturing business. Every year, Foremost Farms produces millions of pounds of cheese, butter, whey and milk protein ingredients from the high-quality milk produced by its members. Its customers represent respected top brands and category leaders at national and regional levels in retail and foodservice channels, that are served with innovative solutions, technical services and customized products. For more information call 800-362-9196 or see foremostfarms.com.
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo’s biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as X (formerly known as Twitter) (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks and @ConcentricByGinkgo), Threads (@GinkgoBioworks) or LinkedIn.
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo’s cell engineering platform. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo’s business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) our ability to realize the expected benefits of merger and acquisition transactions, (vii) the outcome of any legal proceedings against Ginkgo, including as a result of recent acquisitions, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (x) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Ginkgo’s quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 8, 2023 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
GINKGO BIOWORKS INVESTOR CONTACT:
[email protected]
GINKGO BIOWORKS MEDIA CONTACT:
[email protected]
FOREMOST FARMS USA MEDIA CONTACT:
communications@foremostfarms.com
SOURCE Ginkgo Bioworks
cleocin price order erythromycin 500mg top erection pills
cleocin 150mg sale order cleocin 150mg sale cheap sildenafil 100mg
tretinoin gel for sale tadalafil 10mg oral how to get stendra without a prescription
tretinoin for sale online oral retin gel cost avana 200mg
tretinoin cream canada cost tadalis 10mg avana 100mg pills
code promo 1xbet pour bonus https://www.bnbaccess.eu/news/code-promo-1xbet.html
oral cleocin 300mg order erythromycin 500mg generic sildenafil 50mg usa
oral cleocin 300mg cleocin 150mg cheap buy sildenafil 100mg generic
order cleocin 300mg without prescription buy fildena 100mg sale buy fildena paypal
buy retin gel sale order tretinoin gel generic avanafil 100mg over the counter
cheap tretinoin gel tadalafil 20mg pills buy generic stendra
order retin generic retin gel generic avana 100mg over the counter
cleocin 150mg brand erythromycin us sildenafil 100mg drug
order cleocin 300mg generic over the counter ed pills that work buy ed pill
buy tretinoin sale buy tretinoin cream generic purchase avanafil without prescription
order tretinoin cream for sale buy avana 200mg sale buy generic avanafil 100mg
generic tretinoin cream order stendra stendra where to buy
order retin stendra over the counter buy avanafil medication
cleocin order online buy clindamycin paypal buy ed meds
cleocin 150mg canada buy cheap generic cleocin buy sildenafil 50mg without prescription
cleocin online buy cleocin 150mg drug fildena 100mg sale
buy cleocin 300mg generic erythromycin 500mg over the counter buy sildenafil pill
retin gel without prescription buy tadalis generic order avana 200mg generic
buy clindamycin paypal purchase sildenafil pill buy sildenafil online
tretinoin generic avanafil for sale online avanafil 200mg pills
order cleocin 150mg generic buy sildenafil 100mg pills generic ed drugs
buy cleocin 150mg sale erythromycin 500mg usa sildenafil 50mg for sale
retin gel canada avana online order stendra ca
cleocin where to buy purchase erythromycin pills buy fildena pills for sale
order generic cleocin 300mg sildenafil canada erection pills that work
cleocin 150mg brand fildena 50mg without prescription natural pills for erectile dysfunction
Серия ISO 9000 касается требований к управлению предприятием для обеспечения выпуска качественной продукции сертификат соответствия исо 9001 она основывается на 8 принципах.
cleocin usa cost erythromycin low cost ed pills
buy retin gel generic cheap avanafil 200mg avana 200mg sale
cheap cleocin cleocin 150mg without prescription fildena order
buy clindamycin generic buy fildena 100mg for sale sildenafil usa
broo. nice wkwk bro
order cleocin 300mg online cheap clindamycin sale purchase sildenafil pills
buy retin cream order tadalis pills stendra drug
buy cleocin no prescription ed solutions fildena 100mg uk
generic tretinoin gel avanafil canada purchase stendra sale
tretinoin gel brand buy tadalafil 10mg buy generic avana 100mg
cleocin 300mg price order erythromycin 250mg pill online ed pills
clindamycin us cleocin for sale buy fildena 50mg online cheap
legit canadian pharmacy
order cleocin without prescription erythromycin where to buy fildena 100mg uk
buy clindamycin paypal erythromycin us sildenafil 50mg usa
clindamycin drug buy ed pills cheap order sildenafil 100mg online
buy tretinoin gel online cheap avanafil 100mg drug buy stendra medication
order retin cream online cheap buy avana for sale stendra buy online
buy retin online cheap tadalis 10mg sale avanafil 100mg pills
buy clindamycin generic order erythromycin 500mg generic ed pills
retin gel for sale retin cream cheap avana 100mg for sale
%%
Take a look at my web-site – https://carnnews.com/news/andreevka-dron-3-oshbr-podorval-oficerov-rf/271898